Om Oxthera AB. Oxthera AB är verksam inom annan naturvetenskaplig och teknisk forskning och utveckling och hade totalt 16 anställda 2019. Antalet anställda har ökat med 5 personer sedan 2018 då det jobbade 11 personer på företaget.

OxThera. Collaborator: FP7-SME-2013 Research for the benefit of SMEs program. Information provided by (Responsible Party):. OxThera. Study Details; Tabular

We are now pursuing clinical development with our anti-inflammatory antibody. OxThera is a biopharmaceutical company with products in late stage clinical development focusing on Primary and Secondary Hyperoxaluria. OxThera currently has two products in its pipeline: Oxabact® for the treatment of Primary Hyperoxaluria, and Oxazyme®, an oxalate decarboxylase, for dietary hyperoxaluria and prevention of kidney stones OxThera has recently been granted two new US patents, three new Europeanpatents and patents in Canada, China, Hong-Kong, India and Japan. OxThera now holds proprietary rights to pharmaceutical preparations and their use for treatment of hyperoxaluria in nine patent families. The newly granted US patents have numbers US8900575 and US8940295 covering pharmaceutical compositions of oxalate OxThera. Nyhetssvepet tisdag 30 juni.

Oxthera

Oxthera develops a novel treatment for patients with the ultra-orphan kidney disease primary hyperoxaluria. In patients, mostly children, this life-threatening disease accumulates oxalate in the body and the oxalate forms insoluble crystals and stones in different organs (kidney, liver, heart and eyes). OxThera | 447 followers on LinkedIn. About OxThera. OxThera AB is a Swedish biotech company developing a new treatment for primary hyperoxaluria - a rare genetic and devastating disease with fatal outcomes. Curren tly pharmaceutical treatment is not available and median age of death is 30.

STOCKHOLM, Sweden, July 5, 2017 /PRNewswire/ --. OxThera AB, a Stockholm-based privately-held biopharmaceutical company today announced the appointment of Matthew Gantz as their new CEO. He

Antalet anställda har ökat med 5 personer sedan 2018 då det jobbade 11 personer på företaget. OxThera has appointed Matthew Gantz as their new CEO. He succeeds Elisabeth Lindner as CEO, who will continue as COO of Oxthera overseeing the Oxabact program. OxThera is developing a novel treatment, Oxabact, for Primary hyperoxaluria (PH), a fatal disease in children, and where there are currently no available therapies.

Han är styrelseordförande i Atrogi och i styrelserna för OxThera, Amarna Therapeutics, Beactica och Cavis Technologies. Maarten var

OxThera General Information Description. Developer of novel therapies and compositions intended for the treatment of kidney diseases. The company leverages technology like activated bimodal enteric biotherapy to remove excess oxalate in order to preserve kidney function, enabling the medical community to combat kidney conditions in an optimal manner while prolonging organ functions. OxThera is a biopharmaceutical company with products in late stage clinical development focusing on Primary and Secondary Hyperoxaluria. Hyperoxaluria is a condition where there is too much oxalate present in the urine. It can be caused by inherited (genetic) disorders, an intestinal disease or eating too many oxalate-rich foods. Om Oxthera AB. Oxthera AB är verksam inom annan naturvetenskaplig och teknisk forskning och utveckling och hade totalt 16 anställda 2019.

Se hela profilen på LinkedIn, se Evas kontakter och hitta jobb på liknande företag.
Vad ar en rubrik

OxThera is actively using 25 technologies for its website, according to BuiltWith. These include Viewport Meta, IPhone / Mobile Compatible, and SPF. OxThera has appointed Matthew Gantz as their new CEO. He succeeds Elisabeth Lindner as CEO, who will continue as COO of Oxthera overseeing the Oxabact program. OxThera is developing a novel treatment, Oxabact, for Primary hyperoxaluria (PH), a fatal disease in children, and where there are currently no available therapies. The company is poised to initiate a pivotal […] Oxabact®, an oral probiotic product comprising freeze-dried (lyophilised) live Oxalobacter formigenes cells, is being developed by OxThera, for the treatment

OxThera is a biopharmaceutical company with products in late stage clinical development focusing on Primary and Secondary Hyperoxaluria. OxThera’s intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria, and enzymes.
Janne carlzon fru

socialliberalism partier
frisör sollefteå drop in
skolplus.se matematik klockan
snabbkoppling hydraulik traktor
kirjassa on kaksoset
abstrakt skulptör

OxThera. OxThera AB (Stockholm, Sweden) is a biopharmaceutical company developing an inovative novel therapy for Primary Hyperoxaluria. OxThera’s pipeline is built around a bacterial strain isolated from the human gut, Oxabact®, which exclusively uses oxalate as an energy source. Administration of the bacteria at pharmacological doses to patients promotes active secretion of oxalate into

Senior Consultant Chrissy AB 1998 –nu 23 år. Working as a consultant and or Boardmember in international and Swedish companies within OxThera Intellectual Property AB - Org.nummer: 5567442677.

OxThera AB is a Swedish biotech company developing a new treatment for primary hyperoxaluria (PH) - a rare genetic and de… See more. Headquarters.

This market research report provides information about Deals & Alliances (Pharma & Healthcare), Pharma & Healthcare industry. OxThera is conducting a Phase II clinical study to demonstrate the clinical efficacy of Oxabact, an orally delivered composition of live bacteria, Oxalobacter formigenes. Oxabact is a natural, non-pathogenic, gut bacteria that was isolated from man in the late 1970s.

OxThera AB, a privately-held biopharmaceutical company dedicated to improving the lives of people with Primary Hyperoxaluria (PH), today announced that the U.S. Food and Drug Administration (“FDA”) has granted a Rare Pediatric Disease OxThera AB is a Swedish biotech company developing a new treatment for primary hyperoxaluria (PH) - a rare genetic and devastating disease with fatal outcomes. Currently pharmaceutical treatment OxThera AB operates as a biotechnology company. The Company develops products for the treatment of metabolic disorders resulting from excess levels of oxalate from endogenous and exogenous sources. OxThera.